bioAffinity Technologies (BIAF) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
OmniAb is the larger company by market cap ($696.4 million vs $5.5 million), about 126.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIAF | OABI |
|---|---|---|
| Share price | $4.73 | $4.79 |
| Market cap | $5.51M | $696.42M |
| 1-day change | -16.22% | +2.79% |
| YTD return | — | +158.92% |
| 1-year return | — | +163.19% |
| 5-year return | — | -51.96% |
| EPS (TTM) | $-109.35 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $80.70 | $5.43 |
| 52-week low | $4.56 | $1.30 |
| Distance from 52-week high | -94.14% | -11.79% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +73.90% |
| Average volume | 3.73M | 1.47M |
| Shares outstanding | 1.17M | 145.39M |
| Employees | 57 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OmniAb is about 126.3 times larger than bioAffinity Technologies by market value ($696.42M vs $5.51M).
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 57 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
BIAF vs OABI FAQ
Which is bigger, bioAffinity Technologies or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $696.42M compared with $5.51M for bioAffinity Technologies (BIAF).
Are bioAffinity Technologies and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.